Anales de la RANM

297 A N A L E S R A N M R E V I S T A F U N D A D A E N 1 8 7 9 REVISITANDO EL BINOMIO DAPTOMICINA Y ENTEROCOCOS Fernández-Alonso JA, et al. An RANM. 2023;140(03): 284 - 297 21. Munita JM, Tran TT, Diaz L et al. A liaF co- don deletion abolishes daptomycin bacteri- cidal activity against vancomycin-resistant Enterococcus faecalis. Antimicrob Agents Che- mother. 2013;57(6), 2831–2833. https://doi. org/10.1128/AAC.00021-13 22. Humphries RM, Kelesidis T, Tewhey R et al. Geno- typic and phenotypic evaluation of the evolution of high-level daptomycin nonsusceptibility in van- comycin-resistant Enterococcus faecium. Antimi- crob Agents Chemother. 2012; 56(11), 6051–6053. https://doi.org/10.1128/AAC.01318-12. 23. Davlieva M, Zhang W, Arias CA, Shamoo Y. Biochemical characterization of cardiolipin synthase mutations associated with daptomycin resistance in enterococci. Antimicrob Agents Chemother. 2013;57(1), 289–296. https://doi. org/10.1128/AAC.01743-12 24. Rashid R, Cazenave-Gassiot A, Gao IH et al. Comprehensive analysis of phospholipids and glycolipids in the opportunistic pathogen Ente- rococcus faecalis. PloS One. 2017;12(4) https:// doi.org/10.1371/JOURNAL.PONE.0175886 25. Palmer KL, Daniel A, Hardy C, Silverman J, Gilmore MS. Genetic basis for daptomycin re- sistance in enterococci. Antimicrob Agents Chemother. 2011;55(7): 3345–3356. https://doi. org/10.1128/AAC.00207-11 26. Tran TT, Panesso D, Gao H et al. Whole-genome analysis of a daptomycin-susceptible Entero- coccus faecium strain and its daptomycin-resis- tant variant arising during therapy. Antimi- crob Agents Chemother. 2013, 57(1), 261–268. https://doi.org/10.1128/AAC.01454-12 27. Lellek H, Franke GC, Ruckert C et al. Emer- gence of daptomycin non-susceptibility in co- lonizing vancomycin-resistant Enterococcus faecium isolates during daptomycin therapy. Intern J Medical Microbiology: IJMM. 2015; 305(8), 902–909. https://doi.org/10.1016/J. IJMM.2015.09.005 28. Reyes Manrique JC. Contribución del sistema regulatorio de tres componentes liaFSR en la re- sistencia a daptomicina en Enterococcusfaecalis y Enterococcusfaecium. Tesis doctoral. Bogotá. 2014. Disponible en https://repository.javeriana. edu.co/bitstream/handle/10554/15427/Reyes- ManriqueJinnetheCristina2014.pdf ?sequence=1 29. Satlin MJ, Nicolau DP, Humphries RM et al. De- velopment of Daptomycin Susceptibility Break- points for Enterococcus faecium and Revision of the Breakpoints for Other Enterococcal Species by the Clinical and Laboratory Standards Insti- tute. Clinical Infectious Diseases: 2020¸ 70(6): 1240–1246. https://doi.org/10.1093/cid/ciz845 30. Carvajal-Fernández A, Fernández-García M, Aparicio-Hernández RM, García-Luque A. Es- tudio de prescripción-indicación de daptomici- na en el Hospital Central de la Defensa «Gómez Ulla». Sanid. Mil. 2021; 77(4): 198-202. https:// dx.doi.org/10.4321/s1887-85712021000400005 31. Munita JM, Panesso D, Diaz L et al. Correla- tion between mutations in liaFSR of Enterococ- cus faecium and MIC of daptomycin: revisiting daptomycin breakpoints. Antimicrob Agents Chemother. 2012; 56(8): 4354-9. doi: 10.1128/ AAC.00509-12. Si desea citar nuestro artículo: Fernández-Alonso JA, Pedrosa-Corral I, Franco-Acosta A, Expósi- to-Ruíz M, Aznarte-Padial P, Navarro-Marí JM, Gutiérrez-Fernán- dez J. Revisitando el binomio daptomicina y enterococos: impac- to ecológico en un Hospital del Sudeste Español de un antibiótico de último recurso clínico An RANM. 2023;140(03): 284– 297. DOI: 10.32440/ar.2023.140.03. rev06